David Tougeron, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the approach to watch-and-wait surveillance for a patient with mismatch repair deficient (dMMR) locally advanced rectal cancer (LARC) who has achieved a clinical complete response on dostarlimab, outlining the use of regular endoscopy, rectal MRI, and CT scans to monitor for disease progression. Dr Tougeron highlights the importance of frequent evaluations, typically every three months, for at least two years, with the possibility of extending the surveillance interval to every six months thereafter. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.